Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.

@article{Yang2016TargetingAR,
  title={Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.},
  author={Yu Chi Yang and Carmen Adriana Banuelos and Nasrin R. Mawji and Jun Shan Wang and Minoru Kato and Simon Haile and Iain Joseph McEwan and Stephen R. Plymate and Marianne D. Sadar},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 17},
  pages={4466-77}
}
PURPOSE Persistent androgen receptor (AR) transcriptional activity is clinically evident in castration-resistant prostate cancer (CRPC). Therefore, AR remains as a viable therapeutic target for CRPC. All current hormonal therapies target the C-terminus ligand-binding domain (LBD) of AR. By using EPI to target AR activation function-1 (AF-1), in the N-terminal domain that is essential for AR transactivation, we evaluate the ability of EPI to overcome several clinically relevant AR-related… CONTINUE READING